Please Wait...

  • +91 22 2783 1455

  • Product background
    TENOFOVIR DISOPROXIL FUMARATE

WARNING: CAUTION : PLEASE NOTE :
The content or product detailing is not intended to replace advice from your prescribing doctor or healthcare professional. Lavina Pharma is not responsible for such actions by consumers. For any further information about the product please contact +91 22 2783 1455 and we can provide you the details.

TENOFOVIR DISOPROXIL FUMARATE TABLETS 300 MG

HIV-1 infection

Tenofovir disoproxil 300 mg film-coated tablets are indicated in combination with other antiretroviral medicinal products for the treatment of HIV-1 infected adults.

Hepatitis B infection

Tenofovir disoproxil 300 mg film-coated tablets are indicated for the treatment of chronic hepatitis B in adults with:

• compensated liver disease, with evidence of active viral replication, persistently elevated serum alanine aminotransferase (ALT) levels and histological evidence of active inflammation and/or fibrosis.

• evidence of lamivudine-resistant hepatitis B virus.

• decompensated liver disease.


COMPOSITION

Tenofovir Disoproxil Fumarate … 300 mg

Excipients … Q.s.

Color: Titanium Dioxide BP

Method of administration: Oral HIV-1 and Chronic hepatitis B

DOSAGE FOR ADULTS

Adults and adolescents aged 12 to < 18 years and weighing ≥ 35 kg:

The recommended dose of Tenofovir disoproxil for the treatment of HIV or for the treatment of chronic hepatitis B is 300 mg (one tablet) once daily taken orally with food. OR as directed by physician.

SIDE EFFECT

HIV-1 and hepatitis B: In patients receiving tenofovir disoproxil, rare events of renal impairment, renal failure and uncommon events of proximal renal tubulopathy (including Fanconi syndrome) sometimes leading to bone abnormalities (infrequently contributing to fractures) have been reported. Monitoring of renal function is recommended for patients receiving tenofovir.





PRECAUTION

Co-administration of other medicinal products

• Tenofovir disoproxil should not be administered concomitantly with other medicinal products containing tenofovir disoproxil or tenofovir alafenamide.

• Tenofovir disoproxil should not be administered concomitantly with adefovir dipivoxil.

• Co-administration of tenofovir disoproxil and didanosine is not recommended.




PRESENTATION

Tenofovir disoproxil is available in 30 Tablets pack of HDPE jar along with silica gel pouch. Such one jar is packed in a carton along with pack insert.